主动脉瓣置换术后SAM现象机制及相关因素的探讨

目的探讨主动脉瓣置换术后SAM现象的发生机制并对其相关因素进行分析,旨在进一步认识此现象.方法 48例严重主动脉瓣狭窄病人,男26例,女22例;年龄20～58岁.行主动脉瓣置换术后1周内复查超声心动图,以是否出现SAM现象分成两组,对左室舒张末期内径、收缩末期内径、左室流出道内径、室间隔和左室后壁厚度、左室流出道射流速度及压力阶差进行对比.结果无手术死亡.9例左室流出道流速显著增加(大于2.5 m/s),其中6例出现了SAM现象.除左室后壁对比差异无显著性外,其余指标对比差异均具显著性(P＜0.05或0.01).结论主动脉瓣置换术后出现SAM现象与左室流出道流速和压力阶差增大有直接关系,而小左室舒张末期内径、收缩末期内径、流出道内径及增厚的室间隔是SAM现象的主要病理解剖基础.     

Mid-term durability of the Trifecta bioprosthesis for aortic valve replacement

Objective

To clarify the mid-term durability of the Trifecta bioprosthesis for aortic valve replacement (AVR).

主动脉瓣置换术后的SAM现象

目的：报告4例严重主动脉瓣狭窄行主动脉瓣置换术后出现的二尖瓣前叶前向运动（SAM现象），就其产生机制进行了初步探讨，旨在提高对这种现象的认识。方法：自2000年1月至2001年3月，男2例，女2例主动脉瓣严重狭窄病人，年龄20－52岁，平均36．5岁；接受了主动脉瓣置换术，术后均复查超声心动图。结果：4例无手术死亡，均出现SAM现象，导致1例左室流出道严重狭窄，3例少，中量二尖瓣反流，结论：SAM征是肥厚性心肌病中的常见现象，但并非其特有，主动脉瓣狭窄行主动脉瓣置换术后也可产生SAM现象。     

Late results after mitral valve replacement with Mosaic bioprosthesis in patients aged 65 years or younger

Open in a separate window OBJECTIVESAlthough in younger patients indications for biological prosthesis implantation in mitral valve replacement remain controversial, recently bioprostheses use increased considerably. We present late results obtained with the Medtronic Mosaic bioprosthesis in patients aged 65 years or younger. METHODSBetween 2007 and 2017, 67 mitral Mosaic bioprostheses were implanted in patients aged 65 years or younger (58.5 ± 6.4 years). Follow-up extended up to 13 years. Survival, freedom from structural valve degeneration, endocarditis, thromboembolic events and reoperation were considered as main clinical end points evaluated at 1, 5 and 10 years.RESULTSThe mean follow-up was 4.7 ± 2.8 years. Overall mortality rate was 12%. At 1, 5 and 10 years, survival was 94 ± 3%, 89 ± 4% and 77 ± 9%, respectively. Freedom from structural valve degeneration was 100%, 94 ± 4% and 71 ± 21%. Freedom from endocarditis was 95 ± 3%, 90 ± 6% and 84 ± 8%. Freedom from thromboembolic events was 94 ± 3%, 90 ± 5% and 90 ± 5%. Freedom from reoperation was 94 ± 3%, 87 ± 5% and 65 ± 19%.CONCLUSIONSMosaic bioprosthesis appears a valid mitral valve substitute even when employed in ≤65-year-old patients.     

Mid-term clinical and health-related quality of life outcomes for the Trifecta bioprosthesis

BackgroundThe Trifecta valve has been reported to have excellent hemodynamics. Controversy exists on occurrence of patient-prosthesis mismatch (PPM) and data on mid-term outcome is sparse. Health-related quality of life (HRQoL) assessment for the Trifecta valve has not been reported before. The aim of this study was to report the mid-term clinical and HRQoL outcomes in patients undergoing Trifecta valve implantation at our institution.MethodsIn this prospective, observational study, patients undergoing an aortic valve replacement (AVR) using the Trifecta valve were included. Data collection was retrospective from prospectively collected institutional database. Clinical and echocardiographic data were collected prospectively during follow-up. Quality of life was assessed using the Short Form-36 (SF-36) questionnaire.ResultsForty-seven patients were included in the study of which 9 (19%) were women. Isolated AVR was carried out in 33 (70%) patients. In-hospital mortality and 30-day mortality were 1 (2.1%) and 2 (4.2%), respectively. With a mean indexed effective orifice area (iEOA) 0.96 ± 0.1, none of the patients had severe PPM. Moderate PPM was seen in 19%. The mean follow-up was 3 ± 1.7 years. The 5-year survival estimate was 83.2% in the overall cohort, 81.4% in the isolated and 87.5% in the concomitant procedure group. Freedom from re-operation and structural valve degeneration at 5 years was 95.7% and 97.8%. The mean physical health composite was 69.24 ± 2 and the mean mental health composite was 69.7 ± 25, indicating excellent mental and physical well-being among patients.ConclusionThe Trifecta valve provides satisfactory hemodynamics, survival and freedom from re-operation and excellent HRQoL at mid-term follow-up.     

Mitroflow aortic pericardial bioprosthesis — clinical performance

Objective: Advancing life expectancy with the increased prevalence of aortic valve degenerative disease brings the need for an aortic bioprosthesis with excellent haemodynamic performance and comparable durability. The Mitroflow bioprosthesis has been on the worldwide market, except in the United States, since 1982, while the current model (1991) has only recently gained regulatory approval in the latter country. This study was primarily performed to determine the durability of the current Mitroflow bioprosthesis. Methods: The contemporary Mitroflow bioprosthesis was implanted in 381 patients in three centres. The mean age was 76.4 years (range 53–91 years) and the mean follow-up period was 5.4 ± 3.4 years, a total of 2048.7 years of evaluation. Prosthesis–patient mismatch (PPM) was classified by reference effective orifice area index categories: normal ≥0.85 cm² m⁻² (53.9%), mild 0.84–0.76 cm² m⁻² (33.9%), moderate ≤0.75–0.66 cm² m⁻² (11.7%) and severe ≤0.65 cm² m⁻² (0.5%). Results: The survival, at 10 years, was 39.9 ± 7.9% for 50–69 years, 27.0 ± 3.7% for 70–79 years and 16.6 ± 4.4% for ≥80 years (p = 0.011). There was a trend (p = 0.063) influencing survival for moderate-to-severe PPM. Of the independent predictors influencing survival – moderate-to-severe projected effective orifice area index (pEOAI) (Hazard Ratio (HR) 1.6, p = 0.0142) and left ventricular dysfunction (ejection fraction <35%) (HR 1.9, p = 0.0193) were included. The 10-year freedom from structural valve deterioration (SVD) at explant assessing the same age groups as survival was not different (p = 0.081). The 10-year actual/actuarial freedom from SVD, at explant was for ≥60 years – 94.4 ± 1.4% (85.2 ± 3.9%), for ≥65 years – 94.2 ± 1.4% (85.0 ± 4.0%), for 61–70 years – 97.4 ± 2.6% (95.7 ± 4.3%) and for >70 years – 94.0 ± 1.5% (83.2 ± 4.6%). Conclusions: The Mitroflow external mounted, pericardial aortic bioprosthesis with documented excellent haemodynamics (especially for the small aortic root), demonstrates that prosthesis–patient mismatch in moderate and severe categories can essentially be eliminated, with durability performance comparable to other heterograft (porcine and pericardial) bioprostheses.     

Structural valve deterioration after aortic valve replacement with the Trifecta valve

Open in a separate window OBJECTIVESDespite promising short- and mid-term results for durability of the Trifecta valve, contradictory reports of early structural valve deterioration (SVD) do exist. We investigated the incidence of SVD after surgical aortic valve replacement (SAVR) with the Trifecta in our single-centre experience.METHODSData of 347 consecutive patients (mean age 71.6 ± 9.5 years, 63.4% male) undergoing SAVR with the Trifecta between 2011 and 2017 were analysed. Clinical and echocardiographic reports were obtained with a median follow-up of 41 months (1114 patient years).RESULTSIsolated SAVR was performed in 122 patients (35.2%), whereas 225 patients (64.8%) underwent concomitant procedures. The median EuroSCORE II was 4.0 (0.9; 7.1) and 30-day mortality was 3.7% (n = 13). Kaplan–Meier estimates for the freedom of overall mortality at 1, 5 and 7 years were 88.7 ± 1.7%, 73.7 ± 2.6% and 64.7 ± 4.2%, respectively. SVD was observed in 25 patients (7.2%) with a median time to first diagnosis of 73 months. Freedom of SVD was 92.5 ± 0.9% at 5 years and 65.5 ± 7.1% at 7 years. Thirteen patients underwent reintervention for SVD (6 re-SAVR, 7 valve-in-valve), resulting in a freedom of reintervention for the SVD of 98.5 ± 1.1% at 5 years and 76.9 ± 6.9% at 7 years.CONCLUSIONSWe herein report one of the highest rates of SVD after SAVR with the Trifecta. These data indicate that the durability of the prosthesis decreases at intermediate to long-term follow-up, leading to considerable rates of reintervention due to SVD.     

有支架与无支架生物瓣膜行主动脉瓣置换临床对比研究

目的　探讨无支架Medtronic生物瓣行主动脉瓣置换的临床效果。方法　将 6 8例同期施行主动脉瓣置换术病人分为 2组 ,38例行无支架Medtronic生物瓣置换 ,30例对照组行有支架生物瓣置换。术前及术后 2个月随访行超声心动图检查。结果　无支架组和有支架组病人术后各项检测指标差异有显著性意义。无支架组跨瓣压差 (18 0± 3 7)mmHg(1mmHg =0 133kPa)明显低于有支架组(33 7± 8 3)mmHg;左室射血分数 0 6 5± 0 0 5 ,明显高于有支架组 0 5 6± 0 0 8;左室收缩末内径和左室舒张末内径分别为 (3 8± 0 8)cm和 (4 5± 0 4 )cm ,明显低于有支架组 (4 2± 1 4 )cm和 (5 1± 0 9)cm ;无支架组瓣环内径 (2 2 1± 1 8)mm大于有支架组 (19 5± 1 7)mm。结论　无支架Medtronic生物瓣较有支架生物瓣具有较低的跨瓣压差和良好的血流动力学 ,能促进左室功能的恢复。     

Effect of prosthesis-patient mismatch on survival after aortic valve replacement using mechanical prostheses in patients with aortic stenosis

Background  This study assessed the effects of prosthesis-patient mismatch (PPM) after aortic valve replacement (AVR) using mechanical prostheses in patients with aortic stenosis. Methods  A total of 124 patients with aortic stenosis who underwent AVR with mechanical prostheses were followed (mean 9.1 ± 4.9 years). The patients were divided into two groups based on the effective orifice area index (EOAI): Group A did not have significant PPM, defined as an EOAI ≥ 0.85 cm²/m²; and the PPM group had significant PPM, defined as an EOAI < 0.85 cm²/m². Results  In all, 25 patients (20.2%) had PPM. The operative mortality was 6.1% in group A and 12.0% in the PPM group; the difference between the groups was not significant. Moreover, the difference in overall survival rates between group A and the PPM group was not statistically significant (15-year postoperative survival: group A 78.5% vs. PPM group 81.3%). Although there were four late deaths in the PPM group, only one was valve-related. PPM had no effect on late survival. Postoperatively, cardiac function and physical activity levels improved in both groups; the extent of improvement was not dependent on the presence or severity of PPM. Conclusion  Although PPM may affect operative mortality, the effect of PPM appears to decrease over time. PPM had no effect on late survival.     

Mid-term surgical results after valve replacement with the carbomedics valve prosthesis

We present herein a review of 95 patients who underwent valve replacement with the CarboMedics (CM) valve prosthesis between April 1990 and December 1992. The operative mortality for the entire group was 4.2%: 0% following aortic valve replacement (AVR), 2.7% following mitral valve replacement (MVR), and 12.5% following double valve replacement (DVR). All patients were prescribed warfarin and bucolome for anticoagulation, and were followed up for a mean period of 29.9 months. Late mortality was 8.4%: 3.1% following AVR, 10.8% following MVR, and 12.5% following DVR. There were no cases of mechanical prosthetic valve failure, significant hemolysis, infective prosthetic valve endocarditis, or bleeding complications. After 44 months of follow-up, the actuarial freedom from complications was calculated as: thromboembolism, 97.8±1.6%; valve thrombosis, 97.8±1.1%; paravalvular leak, 96.7±1.9%; and reoperation, 98.9±1.1%. The overall survival rate was 84.3±6.3% and all survivors showed a significant improvement in NYHA functional class, from 81% in classes III and IV preoperatively to 99% in classes I and II postoperatively. The CM valve exhibited no significant differences in hemolytic parameters or hemodynamic performance after isolated AVR or MVR compared with the similar type of St. Jude Medical bileaflet valve. The evidence provided by the present study therefore suggests that the CM valve prosthesis can achieve excellent mid-term clinical results and hemodynamic performance with a low incidence of thromboembolism and valve thrombosis.     

主动脉瓣重度狭窄171例外科治疗分析

目的 总结主动脉瓣重度狭窄行瓣膜置换术患者的外科治疗经验.方法 1990年12月至2006年12月共有171例主动脉瓣重度狭窄患者接受主动脉瓣置换术.其中男性135例,女性36例;年龄10-75岁,平均(45.8±15.6)岁;病程2个月-52年.主动脉瓣病变的病因依次为风湿性75例、老年性66例、二叶瓣畸形26例及其他先天性主动脉瓣畸形4例.单独主动脉瓣置换124例,主动脉瓣置换+升主动脉置换7例,主动脉瓣置换+冠状动脉旁路移植5例,主动脉瓣置换+二尖瓣成形19例,主动脉瓣置换+升主动脉成形8例,主动脉瓣置换+主动脉根部拓宽8例(Nicks法).结果 全组患者平均手术时间(4.4±0.6)h,心肺转流时间(124.7±38.5)min,其中主动脉阻断时间(78.3±21.7)min,术中平均出血量(754.5±518.4)ml,所有患者均顺利完成手术并脱离心肺转流.术后早期并发症发生率为12.3%(21/171),包括低心排血量综合征7例,多脏器功能衰竭3例,心内膜炎1例,肾功能不全4例,心室颤动1例,开胸止血2例,Ⅲ度房室传导阻滞2例,纵隔感染1例.全组手术死亡率5.8%(10/171),死于心力衰竭4例,心律失常1例,多脏器功能衰竭4例,感染性心内膜炎1例.结论 主动脉瓣重度狭窄患者的外科治疗对手术技术及围手术期处理经验要求较高,积极行瓣膜置换手术效果满意.     

Pulmonary trunk perforation during transapical minimal invasive aortic valve replacement

In this case report we illustrate our experience with a perforation of the pulmonary trunk during a transapical aortic valve implantation in a single case. The patient suffered from an aortic valve stenosis and was accepted for a minimally invasive procedure because of multiple comorbidities. After unproblematic transapical placement of the aortic valve, a venous bleeding from the anterolateral wound was observed. Median sternotomy showed a bleeding out of the pulmonary trunk that could be stopped with purse-string sutures. The further course of the patient was uneventful.     

人工心脏瓣膜瓣周漏34例临床分析

目的探讨人工心脏瓣膜置换术后瓣周漏的治疗经验。方法分析1993年1月至2005年6月诊治的34例瓣周漏患者的临床资料,其中主动脉瓣位6例,二尖瓣位28例。9例行内科保守治疗,25例因明显贫血和（或）心功能衰竭（心衰）及内科治疗效果不好行外科手术治疗。手术直接修补瓣周漏漏口14例,另10例重新换瓣。结果保守治疗者中,2例在住院期死亡,死因分别为感染性休克、心衰;7例患者随访6～72个月,2例因心衰而死亡,余5例生活良好,超声心动图检查显示漏口无明显变化,心脏各房室无增大,心功能Ⅱ级。手术治疗者中,术中死亡1例,术后死亡3例（12％）;生存的21例患者术后随访4～132个月,1例二尖瓣和1例主动脉瓣瓣周漏修补术后瓣周漏复发,21例均生活质量良好,心功能Ⅱ级。结论对瓣周漏引起症状不严重,对血流动力学影响不明显,心功能良好的患者,可行内科保守治疗,定期随访。对有明显贫血和（或）心功能减退者,应尽早手术治疗。     

Health-related quality-of-life after transapical transcatheter aortic valve implantation

Abstract

Purpose. Transcatheter aortic valve implantation (TA-TAVI) is a well-established treatment for aortic valve stenosis in high-risk patients and indications have been continuously expanding to also include intermediate-risk patients. However, in low-risk patients, experiences are still sparse and although clinical outcomes have been shown favorable results, HRQoL has remained unexplored. The aim of this report was to describe the long-term health-related quality-of-life (HRQoL) in low-risk patients randomized to TA-TAVI or surgical aortic valve replacement (SAVR). Methods. In a prospective, randomized trial, patients with aortic valve stenosis were randomized to either TA-TAVI or SAVR. TA-TAVI was performed through a mini thoracotomy with the introduction of prosthesis via the apex of the heart and antegradely advancement over the pre-dilated native valve. SAVR was performed during cardiopulmonary bypass with resection of the native valve and replacement with a prosthesis valve through a median sternotomy. Afterwards, patients were followed yearly with echocardiography and HRQoL assessment. Results. A total of 58 patients were included; 29 patients for TA-TAVI and 29 patients for SAVR. The only difference in HRQoL was found in the physical component summary after 1 year; 44?±?9 in the TA-TAVI group compared with 36?±?9 in the SAVR group, p?=?.03. There were no differences in any of the remaining timepoints in neither physical nor mental component summary, p?=?.19 and p?=?.98, respectively, and there were no differences in survival during the 5 years. Conclusions. In low-risk patients with aortic valve stenosis undergoing TA-TAVI, no differences appeared in HRQoL compared with SAVR during a 5-year follow-up period.     

Fragmented QRS complex may predict long-term mortality after isolated surgical aortic valve replacement in patients with severe aortic stenosis

 Open in a separate windowOBJECTIVESFragmented QRS (fQRS), related to myocardial fibrosis, is an important prognostic marker of cardiovascular events and mortality. Aortic stenosis (AS), the most frequent valvular heart disease in developed countries, causes myocardial fibrosis due to ventricular pressure overload. The current study aimed to investigate whether fQRS is associated with long-term mortality after isolated surgical aortic valve replacement (SAVR) in patients with severe AS.METHODSA total of 289 patients who underwent SAVR for severe AS between May 2009 and January 2020 with interpretable electrocardiogram were included. Patients were divided into 2 groups according to the presence of fQRS. Kaplan–Meier survival analyses were used to detect cumulative survival rates. Univariable and multivariable Cox proportional hazards models were used to determine the predictors of all-cause mortality.RESULTSfQRS occurred in 126 (43.5%) patients. A total of 59 (20.4%) patients died over a follow-up period of 54 ± 32 months. All-cause mortality was higher in the fQRS group (23 [14.1%] vs 36 [28.6], log-rank test P = 0.002) in the long term. The presence of fQRS [hazard ratio (HR): 1.802, confidence interval (CI): 1.035–3.135, P = 0.037], electrocardiographic left ventricular strain (HR: 1.836, CI: 1.036–3.254, P = 0.038) and history of stroke or transient ischaemic attack (HR: 3.130, CI: 1.528–6.412, P = 0.002) were independent predictors of all-cause mortality in the multivariable Cox regression model.CONCLUSIONSfQRS is associated with a 1.8-fold increase in long-term mortality in patients undergoing isolated SAVR for severe AS. Detecting fQRS in electrocardiograms may provide prognostic information about the long-term outcomes.     

Transapical implantation of a self-expanding aortic valve bioprosthesis — animal feasibility study

Background: Severe peripheral arterial disease may pose a limitation to the applicability of trans-arterial aortic valve implantation in patients who are otherwise candidates. For this reason, transapical aortic valve implantation has been proposed as a possible alternative. Objective: To evaluate the acute safety and performance of a specially designed delivery system, the CoreValve Tranzap™ delivery catheter, for the transapical implantation of a self-expandable aortic valve prosthesis in a porcine animal model. Methods: Thirteen pigs were implanted with a self-expandable aortic valve bioprosthesis using a 21F catheter delivery system through a transapical approach. The delivery system was evaluated for: (1) the ability to access the implantation site; (2) the ability to precisely position the delivery catheter; (3) control of the delivery of the prosthesis; (4) safe retrieval of the delivery catheter; and (5) the ability to close the apical access site of the heart. Results: Successful implantation was achieved in 100% of the cases. The following points were achieved in all animals: (1) passage of the delivery catheter through an incision in the left ventricular apex; (2) positioning of the delivery catheter on the implantation site; (3) controlled deployment of the aortic valve prosthesis; (4) the safe retrieval of the delivery catheter system; and (5) the adequate closure of the apex of the heart. Conclusion: This study demonstrates the acute safety and feasibility of the CoreValve Tranzap™ delivery system for the transapical implantation of the CoreValve self-expanding aortic valve bioprosthesis in a porcine animal model.     

Long-term results for aortic valve replacement with small aortic annulus

We determined whether aortic prosthesis size influences survival and hemodynamic function. Eighty-nine patients who underwent small aortic valve replacement were followed. The small internal orifice area index (IOAI) group was defined as having an internal orifice area/body surface area ratio of < or = 1.3 cm(2)/m(2) (n = 34). The control group was defined as having an IOAI >1.3 cm(2)/m(2) (n = 55). The actuarial survival rate at 10 years was 74.5% in the small IOAI group and 75% in the control group (NS). Freedom from valve-related impairment at 10 years was 87% in the small IOAI group and 85% in the control group (NS). Postoperative pressure gradients were higher in the small IOAI group (p < 0.05). Left ventricular mass index decreased in both groups (albeit nonsignificantly in the small group, but significantly decreased in the control group). The long-term results of aortic valve replacement for patients with small aortic annulus were satisfactory. However, the postoperative pressure gradient through the prosthesis and left ventricular hypertrophy remained at a high level in the small IOAI group.     

Aortic valve replacement in predominant aortic stenosis: What is an appropriate size valve?

Objective This is a retrospective analysis of 94 patients who underwent aortic valve replacement for predominant aortic stenosis between January 1998 and December 2004. Patients and Methods Age ranged from 16 to 70 years (mean 43.2±13.2 years). 73 were male (77.7%). Etiology was rheumatic in 71 (75.5%) and degenerative in 23 (24.5%) patients. On transthoracic echocardiography, the diameter of the aortic annulus ranged from 19 mm to 36mm (mean 28.5±3.0 mm) and the peak systolic gradients ranged from 54 mm to 174 mm of Hg (mean of 109.8±28.8 mmHg). Aortic regurgitation was absent or mild in 76 patients (80.8%) and moderate in rest. A mechanical valve was implanted in 66 patients (70.2%) and a tissue valve in 28 patients (29.8%). Valves of size 23 mm or more were implanted in 75 patients (80%). A valve of 25 mm or larger was implanted in 55 patients (54.3%). Results There were no early deaths. Two patients required permanent pacemaker implantation for complete heart block in the immediate postoperative period. Prosthetic valve thrombosis in one patient was relieved by thrombolysis. Anticoagulant related hemorrhage was seen in two patients. One patient underwent homograft aortic valve replacement for prosthetic valve endocarditis nine months after surgery. Conclusion Isolated aortic valve replacement in patients with predominant aortic stenosis can be performed safely by implanting an adequately large sized prosthesis, without root enlargement in a large majority of patients.     

Triple-valve treatment for prosthetic valve endocarditis occurring 20 years after implantation of a Carpentier-Edwards pericardial bioprosthesis in the aortic valve

A 68-year-old woman had undergone aortic valve replacement and open commissurotomy 20 years previously. At the beginning of 2008, fever, cold, and heart failure symptoms were noted. On blood culture, Streptococcus oralis was detected three times. Surgery was performed under a diagnoses of prosthetic valve endocarditis in the aortic valve, mitral stenosis and insufficiency, and tricuspid insufficiency. Techniques consisted of additional aortic valve replacement, mitral valve replacement, and tricuspid annuloplasty. Vegetation was macroscopically and pathologically observed in the extirpated Carpentier-Edwards pericardial bioprosthesis that had been placed in the aortic valve. There was no postoperative recurrent inflammatory response. The patient was discharged 32 days after surgery.